Company Overview and News

16
BDSI / BioDelivery Sciences International, Inc. FORM 8-K (Current Report)

2018-09-14 sec.gov - 2
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 BDSI

14
BioDelivery Sciences to Host Institutional Investor and Analyst Day on Friday, October 5, 2018

2018-09-13 globenewswire
RALEIGH, N.C., Sept. 13, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that the company will host an Institutional Investor and Analyst Day on Friday, October 5, 2018, at the Lotte New York Palace Hotel in New York.
BDSI

14
BioDelivery Sciences (BDSI) Presents At Rodman & Renshaw.C. Wainwright 20th Annual Global Investment Conference - Slideshow

2018-09-07 seekingalpha
The following slide deck was published by BioDelivery Sciences International, Inc. in conjunction with this event.
BDSI

14
BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

2018-08-21 globenewswire
RALEIGH, N.C., Aug. 21, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that Herm Cukier, Chief Executive Officer will present at the Rodman & Renshaw 20th Annual Global Investment Conference taking place at the St. Regis Hotel in New York, NY.
BDSI

14
BDSI / BioDelivery Sciences International, Inc. / ARMISTICE CAPITAL, LLC - null (Passive Investment)

2018-08-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G
BDSI

14
BDSI / BioDelivery Sciences International, Inc. / ARMISTICE CAPITAL, LLC - null (Passive Investment)

2018-08-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G
BDSI

14
BioDelivery Sciences Secures Significant Expanded Preferred Coverage for BELBUCA®

2018-08-15 globenewswire
RALEIGH, N.C., Aug. 15, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with chronic pain today announced that a leading U.S. pharmacy benefit manager has added BELBUCA® (buprenorphine) buccal film to its national preferred formulary list effective August 15, 2018. BELBUCA is currently indicated in the U.
BDSI

14
BioDelivery's (BDSI) CEO Herm Cukier on Q2 2018 Results - Earnings Call Transcript

2018-08-10 seekingalpha
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Q2 2018 Results Earnings Conference Call August 9, 2018 4:30 PM ET
BDSI

14
BioDelivery Sciences International (BDSI) Reports Q2 Loss, Misses Revenue Estimates

2018-08-09 zacks
BioDelivery Sciences International (BDSI - Free Report) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.
PLNT GD EPE BDSI

14
BDSI / BioDelivery Sciences International, Inc. FORM 10-Q (Quarterly Report)

2018-08-09 sec.gov
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
BDSI

14
BDSI / BioDelivery Sciences International, Inc. 8-K (Current Report)

2018-08-09 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 <
BDSI

14
BDSI / BioDelivery Sciences International, Inc. / Broadfin Capital, LLC - AMENDMENT NO. 3 TO THE SCHEDULE 13D (Activist Investment)

2018-08-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101)
BDSI

14
BDSI / BioDelivery Sciences International, Inc. / Broadfin Capital, LLC - AMENDMENT NO. 3 TO THE SCHEDULE 13D (Activist Investment)

2018-08-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101)
BDSI

32
What's in the Cards for Puma Biotech (PBYI) in Q2 Earnings?

2018-08-07 zacks
Puma Biotechnology, Inc. (PBYI - Free Report) is scheduled to report second-quarter results on Aug 9 after the market closes.
DNLI ACIU PBYI BDSI

15
EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf

2018-08-07 globenewswire - 1
WALTHAM, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced the appointment of Peter Greenleaf to its Board of Directors. Mr. Greenleaf was elected to the Board at the Company’s annual stockholders meeting on July 10, 2018.
EYEG CERC CERCZ EYEGW SCMP BDSI CERCW

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 09060J106